Patients with advanced melanoma are among the first in the world to access pembrolizumab through the early access to medicines scheme (EAMS).
MSD (known as Merck & Co Inc. in the United States and Canada) worked with the MHRA (Medicines and Healthcare products Regulatory Agency) to take the new skin cancer treatment pembrolizumab through the early access to medicines scheme (EAMS). The successful application has led to over 500 patients with advanced melanoma benefiting from the breakthrough treatment before being licensed.
Pembrolizumab was the first medicine to be awarded a positive scientific opinion, which helped to accelerate access to the drug by around 4 months.
Ben Lucas, Business Unit Director, Oncology, MSD said: